Scott+Scott Attorneys at Law LLP Files Securities Class Action Against Charming Medical Limited (NASDAQ: MCTA)

NEW YORK–(BUSINESS WIRE)–$MCTA #CharmingMedical—Scott+Scott Attorneys at Law LLP (“Scott+Scott”), an international securities and consumer rights litigation firm, today announced that it has filed a class action lawsuit against Defendants Charming Medical, Limited; Kit Wong; Ching Man Cheung; Josephine Yan Yeung; Leut Ming Gung; Shu Tai Victor Yu; Cathay Securities Inc.; WWC, P.C.; And Cogency Global, Inc. (collectively, the “Defendants”).

The action, which was filed in the U.S. District Court for the Southern District of New York and captioned Louie v. Charming Medical Ltd., Case No. 1:25-cv-10535, asserts claims under §§10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”) on behalf of a class consisting of all persons and entities, other than Defendants and their affiliates, who purchased Charming Medical Securities between October 21, 2025, and November 12, 2025, inclusive (the “Class Period”), and who were damaged thereby. The lead plaintiff deadline in this action is February 17, 2026.

If you purchased Charming Medical Securities between October 21, 2025, and November 12, 2025, inclusive, and have suffered significant losses, realized or unrealized, you are encouraged to contact Scott+Scott attorney Mollie Chadwick at (619) 798-5307, or via email at [email protected], for more information.

LEAD PLAINTIFF DEADLINE ON FEBRUARY 17, 2026

Charming is a medical company that claims to “enhance the quality of life from the inside out by integrating Traditional Chinese Medicine (TCM) wellness practices with modern technology.” Specifically, by “combining customized TCM-inspired constitution-regulating plans and modern wellness therapies, we provide comprehensive wellness and beauty services and products for women and TCM-inspired therapies tailored for men.” The Company’s stock trades on NASDAQ under the symbol “MCTA.”

The complaint alleges that Defendants violated provisions of the Securities Act arising from the suspension of Charming’s stock in November 2025, following a dramatic yet illusory run-up orchestrated by a fraudulent stock promotion scheme. In the weeks leading up to November 12, 2025, Charming’s share price surged from the initial public offering price (“IPO”) of $4.00 to an all-time high of $29.36 per share, despite no fundamental news from the Company justifying such a spike. Investigations and public reports have revealed that Charming’s stock became the subject of an illicit social-media-based promotion scheme that artificially inflated its price. These reports detail how impersonators claiming to be legitimate financial advisors touted Charming in online forums, chat groups, and through social media posts with sensational, but baseless, claims to create a buying frenzy among retail investors.

LEAD PLAINTIFF DEADLINE ON FEBRUARY 17, 2026

The lead plaintiff deadline in this action is February 17, 2026. If you wish to serve as lead plaintiff, you must move the Court no later than February 17, 2026. Any member of the proposed class may move the Court to serve as lead plaintiff through counsel of their choice or may choose to do nothing and remain a member of the proposed class.

If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiffs’ counsel, Mollie Chadwick at (619) 798-5307, or via email at [email protected].

About Scott+Scott Attorneys at Law LLP

Scott+Scott has significant experience in prosecuting major securities, antitrust, and consumer rights actions throughout the United States and is actively litigating several cryptocurrency cases. The firm represents pension funds, foundations, individuals, and other entities worldwide, with offices in New York, London, Amsterdam, Berlin, Montréal, Connecticut, California, Ohio, Texas, Delaware, Nebraska, and Virginia.

Contacts

Mollie Chadwick

Scott+Scott Attorneys at Law LLP

600 W. Broadway, Suite 3300, San Diego, CA 92101

(619) 798-5307

[email protected]